ICU SeaStar Medical Holding Corp

$ICU I’ve been invested in potential sepsis treatments since I bought MTSB (which became CTSO) back in 2009. Back in 2011, CTSO got EU approval for a cytokine filter, very similar to the SCD, to treat sepsis. The company Mcap shot up 10X, to $300M. EU approval was based on safety data only, not efficacy. The CTSO device has not proven its efficacy for anything yet still sells $30M annually in the EU. If we get US approval for the SCD, I would expect Mcap to be $3B or greater. This current price is a steal.

$ICU Happy I got the chance to add below 3 the last two days, can’t imagine we will see these kind of prices after 22 oct.

$ICU Hello to all the ICU bulls! I’m still with you. The long-time ICU investors will surely remember me—I’m the Italian who has believed in ICU since September 2023. We’re almost there, guys! In the meantime, I’ve managed to lower my average cost... Greetings to everyone from my fantastic Italy! 💪 ICU 💪 One day, we’ll be huge! 🥳💰🌕🌋💯🇮🇹💲

$ICU solid news FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

$ICU currently holding 975 shares at a 3.06 avg. My goal is 2000 shares by end of Q1 2027.

$ICU Upshot: Take out 4 overlapping, and you have 36 different ICU nephrology clinics that have been trained on and using the SCD. Don't tell me that it is not going to become standard of care in no time.

$ICU this better work - I just realized (after buying across a few accounts) - I’m north of 40k.

$ICU Wednsday next week. Congratulations CMO Dr. Kevin Chung, Col. US ARMY(Ret.) A well deserved award for your leadership and dedication to healing our veterans. (Note: The last 3 paragraphs illustrate his specific contributions to serious battlefield injuries and his innovations for treatment) Dr. Kevin Chung's keynote presentation and recognition ceremony at the Update in Critical Care Nephrology 2026 conference—taking place on October 14, 2026, at the Hospital Central de la Defensa in Madrid, Spain—will be managed primarily by the host organization rather than SeaStar Medical. At this conference, Dr. Chung is receiving the prestigious Combat Nephrology Award 2026 and delivering his keynote lecture, “AKI in Military Operations: From Battlefield Experience to Future Strategies,” reflecting his background as a retired U.S. Army Colonel and former Medical Director of the U.S. Army Burn ICU. Release and Coverage Details • The Host's Release: Because this is an academic meeting endorsed by the Spanish Society of Nephrology (S.E.N.), any official documentation, presentation slides, or recap media will be handled directly through the host's institutional channels and official conference registration portals. • SeaStar Medical's Role: Since this presentation focuses on Dr. Chung's historic combat casualty care expertise and military battlefield strategies rather than a regulatory or financial update for the company, SeaStar Medical is not expected to put out an immediate corporate press release for the event. Instead, updates are driven directly by the clinical community on platforms like Jesús Hernández Vaquero's Professional Updates. There is no broad public simulcast or live stream option available for the Madrid meeting, so material access will remain restricted to registered clinical attendees and subsequent post-conference educational archives published by the host. Would you like assistance in finding the official registration or program outline from the Spanish Society of Nephrology for the Madrid event, or are you looking for summaries of Dr. Chung's previously published research on combat-related AKI operations? • X Kevin K. Chung, MD () / X Nephrology 2026 … 🗓️ 14 y 15 de octubre de 2026 📍 Hospital Central de la Defensa, Madrid ➡️Programa e inscripciones: • LinkedIn·Jesús Hernández Vaquero Jesús Hernández Vaquero's Post - Dr. Kevin Chung An internationally recognized expert in burn critical care, combat casualty care, acute organ failure and extracorporeal organ sup... 1. Official Program & Registration for Madrid Event The official event in Spain is the Update in Critical Care Nephrology 2026, a premier clinical conference focused on acute kidney injury and advanced renal support in critically ill patients. • Host and Scientific Endorsements: The conference is organized at the Hospital Central de la Defensa in Madrid. It carries the scientific endorsement of both the Spanish Society of Nephrology (S.E.N.) and the Madrid Society of Nephrology (SOMANE). • Agenda Focus: The meeting runs from October 14–15, 2026. Dr. Chung's keynote session and presentation of the Combat Nephrology Award 2026 will be focal points of the opening day's itinerary. • Registration Portals: Because seating at the defense hospital facility is strictly limited, clinicians must register in advance. You can access details, local programming itineraries, and seat registration directly via the SOMANE Update CCN Portal or the broader S.E.N. Course Directory. 2. Dr. Kevin Chung’s Combat-Related AKI Research Dr. Chung's award in Madrid highlights over two decades of military medicine research pioneered during his time as a U.S. Army Colonel and Medical Director of the U.S. Army Burn Intensive Care Unit. His landmark publications reshape how clinicians manage critical kidney trauma on the battlefield: • Survival Breakthrough with Early CRRT: In a landmark study analyzing severely burned military casualties evacuated from combat theaters (Iraq and Afghanistan), Dr. Chung’s team demonstrated that early, aggressive use of continuous renal replacement therapy (CRRT) significantly dropped 28-day mortality from 75% in historical controls down to 22% in the treatment group. This established CRRT as a vital stabilization tool for combat severe-burn shock. • Quantifying AKI Impact on Warfighters: His research published in clinical literature systematically mapped how acute kidney failure acts as an independent driver of death in combat casualties. By applying standardized RIFLE/AKIN grading scales to military trauma databases, his work proved that severe AKI multi-organ complications drastically amplify ventilator dependencies and intensive care timelines. • The "Burn Navigator" Innovation: Beyond filtration hardware, Dr. Chung co-invented the Burn Resuscitation Decision Support System (Burn Navigator). This FDA-approved algorithmic tool assists frontline medics in delivering precision fluid resuscitation to critically burned casualties, preventing the run-away fluid volumes that historically triggered secondary abdominal compartment syndrome and acute kidney failure on the battlefield. This extensive military track record in controlling hyper-inflammation and organ failure directly underpins his current work implementing the QUELimmune selective cytopheretic filtration platforms for pediatric and adult critical care.

$ICU Don't confuse the company's financial position with the potential of its technology. SeaStar has real challenges: cash burn, dilution and a commercial business that's still in its infancy. Those risks are impossible to ignore. But the product story is getting interesting. QUELIMMUNE revenue grew 82% YoY in Q2, gross margins were around 91%, and the company expanded to 20 children's hospitals. Meanwhile, the adult AKI trial could open a market the company estimates is 50x larger than the paediatric opportunity. Add the FDA's recent Breakthrough Device Designation for adult sepsis-related hyperinflammation, and the platform's potential extends beyond a single indication. The opportunity is clear; execution and funding remain the hurdles. If clinical progress and hospital adoption continue, today's tiny revenue base may not tell the whole story. Promising technology. Early commercial traction. Significant risk but a product thesis worth watching.

$ICU Nice close considering all biotechnology took a severe beating today. It's going to be hard to to sleep knowing we've got Big presents coming next week. Deam Big !

$ICU we just start treating adult sepsis and we are all rich. To newbies: we just got BDD for adult sepsis

$ICU I'm tryin' folks - still buying. Got 4,000 so far today. I might be done for the day. GL longs!

$ICU ya know I really like that picture of the team. These are good, down to earth folks. Be proud of what you are a part of. God speed.

$ICU some great posts in reddit about the SEpSIS BDD!!!! timing thereof!!!! Subset of patient’s with SEPSIS!!! sounds to me like they could have already reached the target needed - enrolled fir this subset???? BDD granted- I assume data is great? dyor

$ICU let’s hope for a nice green week! be grateful for what you have, happy and positive thoughts . I am focussed on getting fit and growing my income! I need to stop dreaming of ICU huge SP! may happen but trying to live in the present❤️ peace

$ICU From Q2 ER "Expanded the use of QUELIMMUNE (SCD-PED) therapy for ultra-rare pediatric AKI, adding 3 new customers from top-rated children's hospitals, bringing the total customer base to 20 and building increased depth in customer orders. This led to second quarter 2026 net revenue of $0.6 million for QUELIMMUNE product sales, an increase of 82% versus the second quarter of 2025. Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial evaluating the SCD therapy as a potential treatment of adult patients with AKI in the ICU receiving continuous renal replacement therapy. The trial has enrolled 223 of 339 patients to date. Completion of enrollment is anticipated around year end or into the first quarter of 2027, which would enable a PMA application to the FDA near the end of 2027, pending a positive outcome of the trial. The new ICD-10-PCS codes are expected to take effect on October 1, 2026. FDA SAVE news Thursday- Looking fwd to Q3 onwards

$ICU working on a starter position here with 10k shares. Hopefully the balance will get filled soon. Only about 2200 filled so far.

$ICU want to invest in the new SOC for sepsis @ 3.00/share with 7-8 million OS? Here you are. Many other massive markets and indications coming as well.

$ICU To get a BDD during the middle of the adult trial for SEPSIS is beyond amazing. Been here for almost 3 years. The other OGs and I have our asses kicked relentlessly. I own a bigger stake than i ever have. Thank you shorties, mms for the opportunity to get back in huge and cheap. Also, i would like to thank the idiot former CFO for all your missteps. Turns out they are a blessing in disguise. Boys we got a BDD for sepsis this week. Could give a fuck less if we closed at $10 or $2.X today.

$ICU so guys Sparky Nikki ballbearer, unity, bullish I know I’m missing a few but would love to meat in Vegas next year when we hit $15-$20 Who’s in .